Role Of Pattern Recognition Receptors And The Microbiota in Neurological Disorders Part 2
Aug 16, 2024
Toll-like receptors
TLRs are a highly expressed family of transmembrane PRRs responsible for initiating downstream signal transduction in response to PAMPs and tissue damage.
Localization of each TLR allows classification into two groups, those expressed on the plasma membrane (TLR1, TLR2, TLR4, TLR5, TLR6, TLR11) and those expressed within the cytoplasm and organelles (TLR3, TLR7, TLR8, TLR9) (Fig. 3).
To date, 11 human and 13 mouse TLRs have been characterized (Akira & Takeda, 2004). Activation of each TLR, following specific PAMP recognition, causes a conformational change in the receptor allowing recruitment of the appropriate downstream signalling adaptor, in turn activating specific transcription factors, and subsequent innate immune responses (Takeuchi & Akira, 2001).
Four adaptor proteins have been identified, each one responsible for a specific immune response. For example, the universal adaptor protein MyD88 is known to induce activation of NF-κB and activator protein 1 (AP-1) triggering the expression of inflammatory cytokines such as tumour necrosis factor-α (TNFα).
Alternatively, TLR3 and TLR4 can signal through the adaptor protein Toll/IL-1 receptor domain-containing adapter inducing interferon-β (TRIF) in order to activate type-I interferon (IFN) (Fitzgerald et al. 2003).
The regulation of these responses is tightly controlled via post-translational modifications such as glycosylation (Weber et al. 2004; Sun et al. 2006; Abdulkhalek et al. 2011; Iavarone et al. 2011) and ubiquitination (Boone et al. 2004; Chuang & Ulevitch, 2004; Shembade et al. 2010; Guedes et al. 2014; Kinsella et al. 2018) and through negative feedback (Scott et al. 1993; Renner & Schmitz, 2009).
Disruption of TLR activation or maturation can lead to dysregulation of the immune response (Barrat et al. 2005; Reynolds et al. 2010; Ziegler et al. 2011; SuarezFarinas et al. 2013; Cavalcante et al. 2018).
Despite continuous exposure to TLR ligands in the gut lumen, IECs express low levels of TLRs. Introduction of pathogenic bacteria causes upregulation of some TLRs, namely TLR2, TLR4, TLR5 and TLR9 (Muzio et al. 2000; Gewirtz et al. 2001; Ewaschuk et al. 2007), while others are differentially expressed in response to pathogenic bacteria.
TLRs play an important role in maintaining host–microbe interactions and mucosal immunity in the GI tract.
Studies are emerging highlighting a novel connection between TLRs and neurodegenerative diseases, including AD, PD and MS. A link between gut microbiota-associated inflammation and brain amyloidosis in AD has been shown, with bacterial amyloids able to initiate expression of inflammatory cytokines (Nishimori et al. 2012).
In AD brains, a higher bacterial LPS load was observed (Zhan et al. 2016) and administration of LPS in mice led to prolonged elevation of amyloid-β and cognitive deficits (Kahn et al. 2012). Further studies have observed increases in amyloid-β in mouse brains alongside alterations in the gut microbiota (Kaji et al. 2010).
LPS-dependent TLR4 signalling is reduced in AD mice, suggesting TLR4 may play a role in disease manifestation (Go et al. 2016). In PD patients, misfolded α-synuclein protein activates microglia via TLR2, activating MyD88-dependent NF-κB signalling, in turn increasing the expression of TLRs. TLR4 also has an observable interaction with α-synuclein and a genetic knockout of TLR4 protected mice from neurodegeneration (Stefanova et al. 2011).
Increased gut permeability and bacterial translocation leading to TLR4 activation in the pre-frontal cortex has been observed in mice with depressive behaviour (Martin-Hernandez et al. 2016). Finally, TLR2 expression is upregulated in both MS patients and, in the mouse model, experimental autoimmune encephalomyelitis (EAE) (Fujiwara et al. 2018).
While the signalling pathways involved are not well understood, TLR2 knock-out mice develop attenuated EAE, suggesting a role for TLR2 (Fujiwara et al. 2018). Studies have found that the microbiota in MS patients is directly responsible for the dysregulation of TLR2 and its subsequent role in pathology (Wasko et al. 2020).
Taken together, these studies indicate the importance of TLR signalling in development of multiple neurological disorders and present novel therapeutic strategies with which to treat them. Our understanding of neurological disorders and the importance of the gut microbiota in their development is continually expanding, with new targets for treatment being identified.
PRRs in particular can make attractive targets due to their function as the first line of defence against pathogens and their dysregulation in many disease pathologies (Mullen et al. 2015).
Targeting of TLR2 signalling by increased TLR2 tolerance in a mouse model of MS significantly enhanced CNS remyelination (Wasko et al. 2019). A loss-of-function mutation in the TLR4 gene was shown to suppress the activation of microglia and monocytes by Alzheimer's amyloid peptides in in vitro studies (Walter et al. 2007).
Melatonin treatment was beneficial in attenuating NLRP3 inflammasome activation following LPS-induced depressive-like behaviours, in part via reduced microglia activation (Arioz et al. 2019). Further studies of the mechanisms these PRRs regulate are needed to identify more targets in the treatment and prevention of many neurodegenerative and neurodevelopmental disorders.
PRRs in other diseases
As well as their role in neurological disorders, PRRs have been implicated in the development of other disorders, including autoimmune diseases. Polymorphisms of both Nod1 and Nod2 have been associated with an increased susceptibility to Guillain–Barre syndrome, an autoimmune disorder that attacks the peripheral nervous system (Kharwar et al. 2016).
Furthermore, increased expression of Nod1 and Nod2 has been noted in the pathogenesis of Vogt–Koyanagi–Harada syndrome, a rare autoimmune disorder (Deng et al. 2016). Additionally, polymorphisms in the NLR family increase the risk of developing IBD, with Nod1 and Nod2 deficient mice displaying an increase in DSS-induced colitis severity (Natividad et al. 2012) and Nod2 mutations correlating with dysbiosis in IBD patients (Aschard et al. 2019).
A single nucleotide polymorphism (SNP) located on chromosome 1q44 downstream of NLRP3 has previously been implicated in increased susceptibility to Crohn's disease (CD) (Villani et al. 2009), but more recent studies in a Chinese Han patient population (Zhang et al. 2014) and a panel of patients in the UK (Lewis et al. 2011) indicate that SNPs in the NLRP3 gene are more closely associated with ulcerative colitis (UC) than with CD.
Despite this, loss-of-function CARD8 mutation in CD patients leads to increased NLRP3 activation, indicating that there may be a role for NRLP3 in CD pathogenesis (Schoultz et al. 2009; Mao et al. 2018). NLRP3−/− mice displayed higher sensitivity to oxazolone-induced colitis, indicating a protective role for the inflammasome in UC (Itani et al. 2016).
In the case of the TLRs, receptor activation and subsequent NF-κB signalling in the gut is important for the survival of enteric neurons responsible for gut motility. Knockout mouse models indicate that TLR4 is important for gut motility, with delayed GI motility associated with decreased numbers of nitrergic neurons (Anitha et al. 2012).
Preliminary studies suggest a role for TLR4 in the development of multiple system atrophy (MSA), where, similar to PD, MSA patients were found to have disrupted tight junction proteins and a higher expression of TLR4 in their colonic sigmoid mucosa when compared to healthy controls (Engen et al. 2017). Taken together, these findings demonstrate the critical role NLRs play in multiple disease pathways, highlighting their potential in maintaining normal physiology.
Conclusions
PRRs, in particular the NLR and TLR families, have been implicated as novel signalling mechanisms in the development of many complex neurological disorders, likely acting in concert with numerous other signalling pathways.
Their high levels of expression in many tissues, in particular the GI tract, make them an attractive target for further study of the gut microbiota and its impact on human health and development of gut–brain function.
Funding
This research was supported by the NIH 1R01AT009365-01 (to M.G.G.).
Biography
Ciara Keogh received her BSc in Genetics (Hons) from Dublin City University in Dublin, Ireland in 2018. During her PhD in University College Dublin, under the supervision of Dr Eoin Cummins, she worked on the effects of carbon dioxide on inflammatory signalling.
She then moved to UC Davis, School of Veterinary Medicine, where she studies the role of antibiotics in the microbiota–gut–brain axis signalling in neonatal mice under the supervision of Dr Melanie Gareau.
References
1.Abdulkhalek S, Amith SR, Franchuk SL, Jayanth P, Guo M, Finlay T, Gilmour A, Guzzo C, Gee K, Beyaert R & Szewczuk MR (2011). Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling. J Biol Chem 286, 36532–36549. [PubMed: 21873432]
2.Akira S & Takeda K (2004). Toll-like receptor signalling. Nat Rev Immunol 4, 499–511. [PubMed: 15229469]
3.Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT & Srinivasan S (2012). Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 143, 1006–1016.e4. [PubMed: 22732731]
4.Arentsen T, Qian Y, Gkotzis S, Femenia T, Wang T, Udekwu K, Forssberg H & Diaz Heijtz R (2017). The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. Mol Psychiatry 22, 257–266. [PubMed: 27843150]
5.Arioz BI, Tastan B, Tarakcioglu E, Tufekci KU, Olcum M, Ersoy N, Bagriyanik A, Genc K & Genc S (2019). Melatonin attenuates LPS-induced acute depressive-like behaviors and microglial NLRP3 inflammasome activation through the SIRT1/Nrf2 pathway. Front Immunol 10, 1511. [PubMed: 31327964]
6.Aschard H, Laville V, Tchetgen ET, Knights D, Imhann F, Seksik P, Zaitlen N, Silverberg MS, Cosnes J, Weersma RK, Xavier R, Beaugerie L, Skurnik D & Sokol H (2019). Genetic effects on the commensal microbiota in inflammatory bowel disease patients. PLoS Genet 15, e1008018. [PubMed: 30849075]
7.Balakrishnan B, Luckey D & Taneja V (2019). Autoimmunity-associated gut commensals modulate gut permeability and immunity in humanized mice. Mil Med 184, 529–536. [PubMed: 30901468]
8.Baquero F & Nombela C (2012). The microbiome as a human organ. Clin Microbiol Infect 18 2–4.
9.Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O & Coffman RL (2005). Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 202, 1131–1139. [PubMed: 16230478]
10.Bersch K, DeMeester K, Zagani R, Wodzanowski K, Reinecker H-C & Grimes C (2020). Bacterial peptidoglycan fragments differentially regulate innate immune signaling. bioRxiv, 10.1101/2020.09.03.278705.
11.Boone DL, Turer EE, Lee EG, Ahmad R-C, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C & Ma A (2004). The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5, 1052–1060. [PubMed: 15334086]
12.Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, Korecka A, Bakocevic N, Ng LG, Kundu P, Gulyas B, Halldin C, Hultenby K, Nilsson H, Hebert H, Volpe BT, Diamond B & Pettersson S (2014). The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 6, 263ra158.
For more information:1950477648nn@gmail.com






